Flint AJ, Meyers BS, Rothschild AJ, et al. - Through a 36-week randomized clinical trial that with 126 persons aged 18 years or older who had an episode of psychotic depression acutely treated with sertraline plus olanzapine for up to 12 weeks, researchers ascertained the clinical influences of maintaining antipsychotic medication after an episode of psychotic depression has responded to combination treatment with an antidepressant and antipsychotic agent. Relapse was experienced by 13 (20.3%) and 34 (54.8%) participants randomized to olanzapine and placebo (plus sertraline), respectively. The impact of olanzapine on the daily rate of anthropometric and metabolic measures significantly varied from placebo for weight, waist circumference, and total cholesterol, however, it was not significantly distinctive for LDL cholesterol, HDL cholesterol, triglyceride, glucose, or HbA1c levels. In conclusion, continuing sertraline plus olanzapine vs sertraline plus placebo lowered the risk of relapse over 36 weeks in patients with psychotic depression in remission. This advantage necessitates being balanced against the potential adverse impacts of olanzapine, like weight gain.